Tata Motors may slide after dismal Q3 result

Image
Capital Market
Last Updated : Feb 08 2019 | 9:04 AM IST

Tata Motors reported consolidated net loss of Rs 26992.54 crore in Q3 December 2018 as compared to net profit of Rs 1198.63 crore in Q3 December 2017. Total income rose 4.37% to Rs 77582.71 crore in Q3 December 2018 over Q3 December 2017. The result was announced after market hours yesterday, 7 February 2019.

In a separate announcement made after market hours yesterday, 7 February 2019, Jaguar Land Rover retail sales in January 2019 were 43,733 vehicles, down 10.9% compared to January last year. Strong sales of E-PACE, IPACE and refreshed Range Rover and Range Rover Sport were more than offset by continuing market weakness in China and the run out of the Range Rover Evoque, ahead of the introduction of the all new Evoque later this quarter.

Aurobindo Pharma's consolidated net profit grew 19.7% to Rs 712.22 crore on 21.2% rise in net sales to Rs 5175.26 crore in Q3 December 2018 over Q3 December 2017. The announcement was made after market hours yesterday, 7 February 2019.

Britannia Industries' consolidated net profit rose 13.8% to Rs 300.07 crore on 10.5% rise in net sales to Rs 2827.40 crore in Q3 December 2018 over Q3 December 2017. The announcement was made after market hours yesterday, 7 February 2019.

New India Assurance reported net loss of Rs 113.52 crore in Q3 December 2018 against a net profit of Rs 617.29 crore in in Q3 December 2017. Net sales rose 8.46% to Rs 5503.06 crore in Q3 December 2018 over Q3 December 2017. The announcement was made after market hours yesterday, 7 February 2019.

Gillette India's net profit fell 8.1% to Rs 53.99 crore on 16.7% rise in net sales to Rs 475.66 in Q2 December 2018 over Q2 December 2017. The announcement was made after market hours yesterday, 7 February 2019.

CEAT said that the company has commissioned the commercial production of the the Truck Bus Radial (TBR) Tyres at the expansion phase of the Halol plant yesterday, 7 February 2019. The announcement was made after market hours yesterday, 7 February 2019.

Sun Pharma Advanced Research Company said it is receipt of an 'Order' from the Office of the Commissioner of GST & Central Excise, Mumbai East Commissionerate, demanding the payment of Service Tax along with Penalty aggregating to Rs 46.04 crore along with interest under section 75 of the Finance Act, 1994. The company would contest the demand and would be filing an appropriate appeal against the Order within the stipulated period. The announcement was made after market hours yesterday, 7 February 2019.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 08 2019 | 8:37 AM IST

Next Story